Table 2 Payoff Matrix for the three parties.
Pharmaceutical companies | Visually impaired individuals | Regulatory authorities | |
|---|---|---|---|
Proactive regulation \((x)\) | Passive regulation \((1-x)\) | ||
Proactive provision \((y)\) | Purchase drugs with Braille-labelled packaging \((z)\) | \({E}_{g}-\gamma {C}_{f}-\varepsilon {C}_{v1}-{C}_{g},\) | \(-\gamma {C}_{f}-\varepsilon {C}_{v1},\) |
\({E}_{f}+\Delta {E}_{f}-\left(1-\gamma \right){C}_{f},\) | \({E}_{f}+\Delta {E}_{f}-\left(1-\gamma \right){C}_{f},\) | ||
\({E}_{v1}-\left(1-\varepsilon \right){C}_{v1}.\) | \({E}_{v1}-\left(1-\varepsilon \right){C}_{v1}-D.\) | ||
Purchase drugs without Braille-labelled packaging \((1-z)\) | \(-\gamma {C}_{f}-{C}_{g}-{R}_{v},\) | \(-\gamma {C}_{f},\) | |
\(-\left(1-\gamma \right){C}_{f},\) | \(-\left(1-\gamma \right){C}_{f},\) | ||
\({E}_{v2}-{C}_{v2}+{R}_{v}.\) | \({E}_{v2}-{C}_{v2}.\) | ||
Passive provision \((1-y)\) | Purchase drugs with Braille-labelled packaging \((z)\) | \({E}_{g}+F-\varepsilon {C}_{v1}-{C}_{g},\) | \(-\varepsilon {C}_{v1},\) |
\({E}_{f}-F,\) | \({E}_{f},\) | ||
\({E}_{v1}-\left(1-\varepsilon \right){C}_{v1}-D.\) | \({E}_{v1}-\left(1-\varepsilon \right){C}_{v1}-D.\) | ||
Purchase drugs without Braille-labelled packaging \((1-z)\) | \(F-{C}_{g}-{R}_{v},\) | \(0,\) | |
\(-F,\) | \(0,\) | ||
\({E}_{v2}-{C}_{v2}+{R}_{v}.\) | \({E}_{v2}-{C}_{v2}.\) | ||
